Clinical Trial for Ebola Drug Starts in Liberia


Scientists have started testing an experimental drug for Ebola in a Liberian hospital.

University of Oxford researchers have launched a trial of the drug, brincidofovir, in Doctors Without Borders’ Ebola center in Monrovia. The drug has previously been used to treat patients with Ebola in the United States, like Thomas Eric Duncan, NBC cameraman Ashoka Mukpo, and Dr. Craig Spencer.

When patients at the unit are informed they have Ebola, they will be offered the opportunity to participate in the trial. Patients who volunteer will be given two weeks of brincidofovir. The researchers estimate there will be about 140 participants. “Typically it takes over 18 months to start a trial. Here we have done it in less than four months,” Trudie Lang, an Oxford University professor, said in a statement. “Everyone has pulled together to make it happen—a Herculean effort by all those involved.”


View original post 89 more words

C3 Glomerulonephritis

Over the past 40 years, nephrologists and pathologists alike have consistently emphasized that membranoproliferative glomerulonephritis (MPGN) is not a diagnosis per se but rather a histopathologic pattern of injury that in turn requires the clinician to seek out potential underlying causes of injury. Until recently, the major clinical classification for MPGN divided patients into secondary cases, when an underlying aetiology could be identified (for example, systemic lupus erythematosus, hepatitis C virus infection, and cryoglobulinaemia), and idiopathic or primary cases, when no such aetiology was present. For primary disease with an MPGN pattern, a histopathologic classification of type I, type II, and type III was used, based largely on the ultrastructural appearance and location of electron-dense deposits. Neither classification scheme was founded on an understanding of the pathogenesis of the disease process. Therapy was largely empiric or selected on the basis of results from trials of patients whose biopsy samples looked similar by light microscopy despite the fact that the findings had the potential to have very different aetiologies. Some of the largest and most influential treatment trials of MPGN included patients with type I MPGN and those with type II MPGN (dense deposit disease [DDD]), despite strong sentiment that type II MPGN was a unique entity and unrelated to type I MPGN.

Over the past decade, improved understanding of the role of complement in the pathogenesis of a number of glomerular diseases has led to progress in disease classification and treatment. For example, in patients with a thrombotic microangiopathy on renal biopsy, clinicians now attempt to determine if the patient has thrombotic thrombocytopenic purpura (TTP) with a low level of ADAMTS13 (the von Willebrand factor cleaving protease), Shiga-toxin-positive haemolytic uremic syndrome (HUS), or atypical HUS in which persistent activation of the alternative complement pathway leads to the thrombotic microangiopathy. Understanding the role of the alternative complement pathway in MPGN has illuminated the entire field and led to a paradigm shift in classification. A proposed reclassification of MPGN into immunoglobulin-mediated disease, driven by classical complement pathway activation, versus non-immunoglobulin-mediated disease, fuelled by alternative complement pathway activation, has led to improved diagnostic algorithms and the emergence of a new grouping of diseases called the C3 glomerulopathies. This improved understanding of MPGN and, in particular, the heightened focus on the activity of the alternative complement pathway in the C3 glomerulopathies will, ideally, lead to improved outcomes in these diseases. (1)

C3 GN is part of the same family as dense deposit disease (DDD) and fall into the new classification of C3 glomerulopathy. Compared to C3 GN, DDD is characterized by extremely electro-dense intra-membranous deposits on EM. Both entities can present with features of MPGN, once significant chronic endothelium glomeruli damage occurs. These glomerular pathologies shared in common its pathogenesis, which involves complement dysregulation.

Classically, immunoglobulins that deposit in the glomeruli are the major triggers of glomeruli inflammation. In rare settings such as C3 GN, complement proteins are present in the glomerular lesions in the absence of immunoglobulins. Abnormal activation of the alternative pathway is implicated on this finding. Either an acquired or inherited defect in the control of alternative complement pathway should be investigated.

The following tests are generally recommended:

  • Levels of C3 and complement factors B/H/I
  • Presence of C3 nephritic factor (C3 NeF)
  • Genotyping for certain complement mutations (common in children)

Circulating C3 nephritic factor is an IgG autoantibody that directly stabilizes the C3-convertase activating complex of the alternative pathway and thereby prevents the normal inhibitory action of complement factor H, leading to continuous activation of the complement cascade and consequent deposition of complement by-products in the glomeruli.

Although atypical hemolytic uremic syndrome (aHUS) is also strongly associated with a dysregulation of the alternative pathway, glomerular lesions in aHUS do not exhibit C3 deposits or electro-dense deposits on electron microscopy, differentiating from C3 glomerulopathies. How changes in complement regulation leads to very diverse presentations might be related to the underlying defect. Nonetheless, atypical HUS could be placed in one side of this spectrum of renal diseases associated with alternative complement dysregulation(2) (figure below; adapted from Servais et al. 2007).


C3 Comp pathway

For more information, click here.

(1) Nature Reviews Nephrology 8, 634-642 (November 2012) | doi:10.1038/nrneph.2012.213 (2)

Promising Antibiotic on the Horizon!

Teixobactin – Never heard of it? It might become a common household name such as vancomycin and Zosyn in the near future based on promising findings published in Nature this week. Using samples from dirt and novel techniques, Teixobactin was isolated. The authors described how successful the antibiotic was against MRSA and drug resistant TB in cell cultures and mice and without signs that the bacteria would develop resistance. Check out a summary from The Washington Post and the Nature article itself!

“New class of antibiotic found in dirt could foil resistant bacteria strains
The new antibiotic could be used for decades against MRSA and drug-resistant TB before they get wise.”

Lung Abscess

  • Clinical Manifestations: most present with indolent symptoms that evolve over a period of weeks or months.
    • Common symptoms: fever, cough, and sputum production
    • Less common: pleurisy, hemoptysis
  • Pathogens:
    • Typically polymicrobial
    • Commonly Anaerobic (Bacteroides, Fusobacterium, Prevotella) – expected, as above, to have an indolent course
    • Also, MRSA, streptococcus, klebsiella, nocardia, coccidiomycosis, and cryptococcus
    • Approximately one-third of patients died, another one-third recovered, and the remainder developed debilitating illness with recurrent abscesses, chronic empyema, bronchiectasis, or other sequelae.
  • Diagnosis:
    • Imaging (i.e. CT)
    • Would NOT attempt sampling the fluid bronchoscopically due to risk of forming a bronchopleural fistula
  • Therapy:
    • Medications:
      • Consider treating empirically due to likely polymicrobial nature
      • Beta-lactam + beta-lactamase inhibitor
      • Clindamycin
      • Linezolid if there is concern for MRSA (vancomycin is an alternative agent)
      • Metronidazole does not work
    • Surgery: Rarely required, except for a few situations
      • Large size (>6cm)
      • Obstructed bronchus
      • Resistant organism (i.e. Pseudomonas)